Patents Assigned to WELT BIO-MOLECULAR PHARMACEUTICAL, LLC.
  • Antibodies targeting B-cell receptor complex membrane bound IgM and uses thereof
    Patent number: 10227419
    Abstract: The present invention relates to antibodies targeting the membrane bound IgM (mIgM) of the B-cell receptor complex found in B-cell lymphomas and leukemias and uses thereof. Another aspect of the present invention is the use of anti-B-Cell mIgM antibodies in the treatment of Be-cell malignancies, including B-cell lymphomas and leukemias.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: March 12, 2019
    Assignee: Welt Bio-Molecular Pharmaceutical, LLC.
    Inventors: Sydney Welt, David Kostyal, Rachel S Welt, Virginia Raymond, Jonathan A Welt
  • Antibodies targeting B-cell receptor complex membrane bound IGM and uses thereof
    Patent number: 9926381
    Abstract: The present invention relates to monoclonal antibodies targeting the membrane bound IgM (mIgM) of the B-cell receptor complex found in B-cell lymphomas and leukemias. Monoclonal antibodies designated mAb4-2b, mAb1-1, mAb2-2b and mAb3-2b were produced by hybridoma cell lines (ATCC deposit no. PTA-121716), (ATCC deposit no. PTA-121719), (ATCC deposit no. PTA-121717), and (ATCC deposit no. PTA-121718), respectively. Another aspect of the present invention is the use of anti-B-Cell mIgM antibodies in the treatment of B-cell malignancies, including B-cell lymphomas and leukemias.
    Type: Grant
    Filed: December 1, 2014
    Date of Patent: March 27, 2018
    Assignee: WELT BIO-MOLECULAR PHARMACEUTICAL, LLC.
    Inventors: Sydney Welt, David Kostyal, Rachel S Welt, Virginia Raymond, Jonathan A Welt